Canadian Agency for Drugs and Technologies in Health. (2019). Clinical review report: Ertugliflozin (Steglatro) (Merck Canada Inc.): Indication : type 2 diabetes mellitus (Final (with redactions).). Ottawa (ON): CADTH.
Chicago Style CitationCanadian Agency for Drugs and Technologies in Health. Clinical Review Report: Ertugliflozin (Steglatro) (Merck Canada Inc.): Indication : Type 2 Diabetes Mellitus. Final (with redactions). Ottawa (ON): CADTH, 2019.
MLA CitationCanadian Agency for Drugs and Technologies in Health. Clinical Review Report: Ertugliflozin (Steglatro) (Merck Canada Inc.): Indication : Type 2 Diabetes Mellitus. Final (with redactions). Ottawa (ON): CADTH, 2019.
Warning: These citations may not always be 100% accurate.